1. Home
  2. ABUS vs SBGI Comparison

ABUS vs SBGI Comparison

Compare ABUS & SBGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.73

Market Cap

839.5M

Sector

Health Care

ML Signal

HOLD

Logo Sinclair Inc.

SBGI

Sinclair Inc.

HOLD

Current Price

$15.09

Market Cap

998.0M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABUS
SBGI
Founded
2005
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Broadcasting
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
839.5M
998.0M
IPO Year
2008
2023

Fundamental Metrics

Financial Performance
Metric
ABUS
SBGI
Price
$4.73
$15.09
Analyst Decision
Strong Buy
Buy
Analyst Count
1
5
Target Price
$5.00
$22.00
AVG Volume (30 Days)
2.3M
516.1K
Earning Date
05-14-2026
04-30-2026
Dividend Yield
N/A
6.56%
EPS Growth
55.26
N/A
EPS
0.87
0.28
Revenue
$14,083,000.00
$3,169,000,000.00
Revenue This Year
N/A
$12.37
Revenue Next Year
$239.71
N/A
P/E Ratio
$5.52
$50.89
Revenue Growth
128.21
N/A
52 Week Low
$3.08
$11.89
52 Week High
$5.10
$17.88

Technical Indicators

Market Signals
Indicator
ABUS
SBGI
Relative Strength Index (RSI) 64.91 61.69
Support Level $4.15 $14.54
Resistance Level $4.85 $15.49
Average True Range (ATR) 0.18 0.60
MACD 0.05 0.13
Stochastic Oscillator 85.54 92.59

Price Performance

Historical Comparison
ABUS
SBGI

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About SBGI Sinclair Inc.

Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.

Share on Social Networks: